SHARE / this issue Key figures Shareholder information Financial calendar SELECT results show semaglutide 2.4 mg significantly reduces major adverse cardiovascular events Novo Nordisk continues investments to expand production capacity 2 SHARE Magazine • 2/2023
Download PDF file